The Role of Red Yeast Rice Based Preparations for Non-Pharmacological Correction of Dyslipidemia in Patients with Low and Moderate Cardiovascular Risk (Expert Opinion)
暂无分享,去创建一个
S. Shalnova | C. Escobar | O. Drapkina | A. Catapano | V. Kukharchuk | A. Starodubova | A. Alieva | M. Ezhov | V. Gurevich | O. Bolshakova | M. Voevoda | V. S. Gurevich | O. Oynotkinova | I. Shaposhnik | Kukharchuk Vv | O. Drapkina | O. Drapkina
[1] D. Panagiotakos,et al. The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. , 2019, Atherosclerosis. Supplements.
[2] M. Sabatine,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.
[3] Chunjie Wu,et al. Quality and Authenticity Control of Functional Red Yeast Rice—A Review , 2019, Molecules.
[4] A. Sahebkar,et al. Safety of red yeast rice supplementation: A systematic review and meta‐analysis of randomized controlled trials , 2019, Pharmacological research.
[5] J. Espín,et al. Re-examining the role of the gut microbiota in the conversion of the lipid-lowering statin monacolin K (lovastatin) into its active β-hydroxy acid metabolite. , 2019, Food & function.
[6] M. Banach,et al. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER? , 2019, Cardiovascular research.
[7] Odyssey Outcomes Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018 .
[8] M. Banach,et al. Optimizing Cholesterol Treatment in Patients With Muscle Complaints. , 2017, Journal of the American College of Cardiology.
[9] Lale Tokgözoğlu,et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.
[10] E. Raschi,et al. Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system , 2017, British journal of clinical pharmacology.
[11] M. Banach,et al. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction. , 2017, Journal of the American College of Cardiology.
[12] A. Keech,et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.
[13] M. Banach,et al. Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. , 2016, International journal of cardiology.
[14] A. Hahn,et al. Low daily dose of 3 mg monacolin K from RYR reduces the concentration of LDL-C in a randomized, placebo-controlled intervention. , 2016, Nutrition research.
[15] Doughari Jh. The Occurrence, Properties and Significance of Citrinin Mycotoxin , 2015 .
[16] V. Gerdes,et al. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. , 2015, Atherosclerosis.
[17] R. Brook,et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. , 2015, Journal of the American College of Cardiology.
[18] M. Banach,et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel , 2015, Expert opinion on drug safety.
[19] G. V. Artamonova,et al. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ) , 2017 .
[20] Jyh-Chin Yang,et al. Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin , 2012, Evidence-based complementary and alternative medicine : eCAM.
[21] M. Gnant,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .
[22] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[23] T. Hagve,et al. HypoCol (red yeast rice) lowers plasma cholesterol – a randomized placebo controlled study , 2010, Scandinavian cardiovascular journal : SCJ.
[24] D. Capuzzi,et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. , 2008, The American journal of cardiology.
[25] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[26] K. Hasumi,et al. Monacolins J and L, new inhibitors of cholesterol biosynthesis produced by Monascus ruber. , 1985, The Journal of antibiotics.